Please login to the form below

Live webinar: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum

Thursday 21st March 2019
15:00 GMT / 16:00 CET

Register now to secure your place »

The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several other candidates reach late-stage development.

Analysis of Therapy Watch data, a real-time’ syndicated market tracking tool from Research Partnership, shows that JAK inhibitors have already made a strong impression in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake.

This pharmaphorum webinar, held in conjunction with Research Partnership, will use the latest intelligence from both physicians and patients to look at emerging trends in the RA market, how these will shape the RA market of tomorrow and how companies can best position themselves for future success.

Focus
The webinar will be held on Thursday 21st March from 15:00-16:00 GMT and will provide an opportunity to interact with the panel about how companies can best harness the potential of this increasingly complex, but highly rewarding, market.

Topics to be covered include:

  • The European RA market
  • Current status and market situation of JAK inhibitors (key EU5 countries)
  • Uptake curve of JAKs compared to other new entrants and biosimilars
  • Profile of physicians prescribing JAKS
  • Country differences
  • The future of new classes of JAK inhibitors

Thursday 21st March 2019
15:00 GMT / 16:00 CET

Register now to secure your place »

1st March 2019

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Webcast: Influencing HCP behaviours – Is now the perfect opportunity?
Putting behavioural science at the forefront of market research
Research Partnership
Quantitative specialist joins Research Partnership, London
Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London
Research Partnership
Webcast
Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights
Research Partnership
Webcast
The power of a good story: Turn your insights into effective storytelling with data visualisation
Research Partnership
Article
How will COVID-19 affect uptake of vaccinations against other diseases?
Research Partnership
Podcast
Living With Chronic Illness (Series one)
Research Partnership